Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates
Sensei Biotherapeutics (FTH) reported third-quarter GAAP earnings per share of -$0.79, missing analyst expectations by $0.01. Despite the slight earnings miss, the company demonstrated a significant increase in its liquidity position. As of September 30, 2026, Sensei Biotherapeutics held $174.8 million in cash, cash equivalents, and marketable securities, a substantial rise from the $21.2 million reported as of December 31, 2025. The company continues to focus on its lead assets, including Faeth Therapeutics' PI3K pathway inhibitor developments.
Coverage
- Ovid Therapeutics Reports Q3 GAAP EPS of -$0.10, Missing Estimates by $0.02
- ArriVent BioPharma Reports Third Quarter GAAP EPS of -$0.81
- Annexon Biosciences Reports Third Quarter GAAP EPS of -$0.25 and Updates Clinical Trial Progress
- Corvus Pharmaceuticals Reports Q3 GAAP EPS Miss Amid Significant Cash Increase
- Shattuck Labs Reports Q3 GAAP EPS Miss Amid Increased Cash Reserves
- Spyre Therapeutics Reports Q3 GAAP EPS of -$0.94, Missing Estimates by $0.11
- Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates
- Dream Impact Trust Reports Q3 GAAP EPS of -$0.35, Missing Estimates by $0.15